Added to YB: 2026-05-12
Pitch date: 2026-05-10
PTCT [neutral]
PTC Therapeutics, Inc.
+2.63%
current return
Author Info
No bio for this author
Company Info
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
Market Cap
$6.1B
Pitch Price
$74.88
Price Target
N/A
Dividend
N/A
EV/EBITDA
5.5K
P/E
-31.82
EV/Sales
8.39
Sector
Biotechnology
Category
growth
Q1 Earnings Wire May 8, 2026 PM Drop - PTC Therapeutics, Inc.
PTCT (earnings): Q1 rev $273M, product rev $226M (+47% YoY). Sephience $125M (+36% QoQ), 1,244 patients, ~140 new starts/mo US, Japan sales launched. Translarna $59M, Evrysdi royalty $46.8M. Cash $1.89B. PIVOT-HD votoplam showed 52% slower cUHDRS progression (Novartis pays $50M milestone Q2). FY26 product rev guide raised to $750-850M, total rev $1.08-1.18B. Stock +14.27%.
Read full article (1 min)